Prebiotic Spotlight: Gut Health

In this edition of the Global Prebiotic Association’s (GPA) Prebiotic Spotlight, focus is placed on the concept of “Gut Health”, a term that has been widely used but, until recently, lacked a structured and standardized definition. This report explores the new definition and highlights some noteworthy points shared in the newly published consensus definition. 

Overview 

For years, “gut health” has functioned as a ubiquitous catchphrase within the consumer wellness industry. Frequently used in marketing as a vague synonym for general “wellness” or “regularity,” the term has historically lacked a rigorous scientific foundation, leading some companies to leverage poorly defined metrics or overpromise the results. This ambiguity created a significant gap between consumer expectations and clinical reality, as scientists lacked a unified framework to measure what a “healthy” gut looked like across different populations. Without a standardized definition, researchers struggled to compare results between clinical trials, and regulatory bodies lacked a standardized evidence-based framework to validate and safeguard health claims.  

To address this challenge, the International Scientific Association for Probiotics and Prebiotics (ISAPP) published a consensus paper in 2026 proposing a standardized definition of “gut health” and outlining a framework of domains and metrics to assess what constitutes a healthy gut. This work represents an important advancement for the prebiotic industry by helping to align commercial communication with objective scientific evidence.  

The New Consensus Definition 

Gut health, as defined by ISAPP, is “a state of normal gastrointestinal function without active gastrointestinal disease and gut-related symptoms that affect quality of life” (Marco et al., 2026).  

This definition represents an important development in the scientific and regulatory landscape. Rather than relying on a traditional “absence of disease” model, it introduces a dynamic, functional framework that considers gastrointestinal function and symptom burden in relation to quality of life. In this framework, functional, subjective, and extrinsic criteria are utilized, where an individual’s lived experiences and symptom profiles contribute to the characterization of gut health, alongside objective mechanistic markers.   

GPA supports ISAPP’s efforts to establish a standardized framework for gut health. By defining gut health through distinct and measurable parameters, this framework may help advance greater consistency in clinical evaluation and research models, while reducing the occurrence of ambiguous product claims.   

The Six Domains of Gut Health  

To capture the full complexity of gastrointestinal function, ISAPP proposed categorization of gut health into six interconnected biological domains, each evaluated by distinct clinical metrics: 

• Digestive Physiology: Evaluated via metrics of motor and secretory function, including salivary, gastric, biliary, pancreatic, and intestinal secretions, alongside gastric and intestinal motility. 

• Gut Microbiome: Measured through compositional and abundance analyses of resident taxa, specifically tracking metabolite production levels and the presence of pathogenic strains. 

• Gut Barrier Integrity: Assessed using various permeability parameters. 

• Immune Function: Evaluated via specific and non-specific inflammatory markers across both mucosal and intestinal pathways. 

• Metabolism: Measured through metabolic signalling indicators, specifically circulating levels of metabolic hormones glucagon-like peptide-1 and peptide YY. 

• Gut-Brain Axis: Assessed via stress-response measures, the perceived stress scale, tryptophan metabolites, and functional gut-brain modules.  

Prebiotics: Mechanistic Roles Across the Domains  

GPA defines a prebiotic as “a compound or ingredient that is utilized by the microbiota producing a health or performance benefit” (Deehan et al., 2024). Modern prebiotic science demonstrates that these ingredients exert functional effects that extend beyond the local gastrointestinal tract to influence distant organs and systemic pathways.  

The standardized ISAPP framework allows for a more nuanced understanding of how specific prebiotic interventions modulate individual domains of gut health and support internal equilibrium.  

• Microbiome Modulation: While prebiotics were historically linked almost exclusively to the modulation of Bifidobacteria and Lactobacilli, accumulating evidence demonstrates that carbohydrate and non-carbohydrate prebiotic ingredients may modulate a diverse array of resident microbial taxa. Prebiotics have been shown to enrich beneficial species such as Roseburia, Faecalibacterium, Bacteroides, Akkermansia, and specific beneficial Clostridia strains, while simultaneously reducing the abundance of pathogenic microorganisms including Escherichia coli and Helicobacter pylori (Alves-Santos et al., 2020; Deehan et al., 2017; Plamada & Vodnar, 2021).  

• Metabolism: A defining characteristic of prebiotics is their ability to enrich short-chain fatty acid (SCFA)-producing bacteria and promote microbial fermentation. The primary by-products of this fermentation are the SCFAs acetate, propionate, and butyrate, which function as energy reservoirs and signaling molecules. These metabolites have been associated with modulation of endocrine, immune, musculoskeletal, and respiratory systems (Hughes & Holscher, 2021; Schroeder & Backhed, 2016).   

• Immune Function and Barrier Integrity: Prebiotics may contribute to the modulation of host immune responses, mitigation of systemic inflammation, and support of gut barrier integrity. Mechanistically, certain prebiotic ingredients may increase anti-inflammatory cytokines while downregulating proinflammatory cytokines (Perreau et al., 2023). Clinically, these actions have been shown to reduce the incidence, duration, and symptom severity of certain respiratory and gastrointestinal complaints (Parker et al., 2023; Zhang et al., 2023).  

Conclusions  

GPA supports ISAPP’s initiative to standardize the definition of “gut health”. By establishing a clear and multidimensional framework, the prebiotic industry may be better positioned to navigate unique product claims using robust and validated science. This shift may ultimately support the advancement of scientific research, enhance clinical trial design, assist in setting regulatory frameworks for safeguarding consumer products, and promote long-term consumer confidence and trust.